The Global Tribune

Graft Versus Host Disease (GVHD) Market Size is expected to grow at a CAGR of 15.9% in 7MM for the Study Period of 2018-30| AstraZeneca, Biogen, Amgen, Pfizer, Roche, Genentech, Bristol-Myers Squibb

 Breaking News
  • No posts were found

Graft Versus Host Disease (GVHD) Market Size is expected to grow at a CAGR of 15.9% in 7MM for the Study Period of 2018-30| AstraZeneca, Biogen, Amgen, Pfizer, Roche, Genentech, Bristol-Myers Squibb

June 10
15:10 2021
Graft Versus Host Disease (GVHD) Market Size is expected to grow at a CAGR of 15.9% in 7MM for the Study Period of 2018-30| AstraZeneca, Biogen, Amgen, Pfizer, Roche, Genentech, Bristol-Myers Squibb

Graft Versus Host Disease Market

Graft Versus Host Disease is an immune condition that occurs when immune cells (T-cells) after transplant procedures from the donor (known as the graft or graft cells) attack the recipient patient host’s tissues (healthy cells); the disease is a side effect that is common after an allogeneic bone marrow transplant (stem cell transplantation).

The two main types of GVHD are Acute GVHD and Chronic GVHD. Other than this, GVHD is classified into other types, namely: Classic Acute GVHD, Persistent, Recurrent, Late-Onset Acute GVHD, Classic Chronic GVHD, And Overlap Syndrome and De Novo Chronic GVHD.

DelveInsight’s ‘Graft Versus Host Disease Market Insights, Epidemiology, and Market Forecast 2030’ report delivers an in-depth understanding of the GVHD, historical and forecasted epidemiology as well as the GVHD market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), and Japan.

 

Key Facts of Graft Versus Host Disease Market Report are:

  • In 2020, the 7MM reported 24,049 allogeneic cases, with a CAGR projecting increase in cases by 2030.
  • The United States accounted for 9,857 allogeneic cases in 2020, representing the highest percentage, of all allo-HSCT in the 7MM.
  • GVHD is categorized into two types: aGVHD and cGVHD.
  • In 2020, acute GVHD cases accounted for 11,638, while chronic cases accounted for 7,854. In the 7MM, the aGVHD and cGVHD cases are expected to rise to by 2030 during the forecast period, i.e., 2021–2030. Germany has the highest number of cases of GVHD by type (acute and chronic) among the EU-5 nations, with 2,984 in 2020.
  • The GVHD market size in the 7MM is expected to change during the study period 2018–2030, at a CAGR of 15.9%.
  • DelveInsight estimates, the highest market size of GVHD is accessed in the United States followed by Japan and Germany, in 2020.

 

Request for free Sample Report: https://www.delveinsight.com/sample-request/graft-versus-host-disease-gvhd-market

 

Some of Graft Versus Host Disease Companies are:

  • Medac
  • MaaT Pharma
  • ElsaLys Biotech (Mediolanum Farmaceutici Spa)
  • Syndax Pharmaceutical
  • Kadmon Corporation
  • AstraZeneca
  • Biogen
  • Amgen
  • Pfizer
  • AltruBio
  • CSL Behring
  • Incyte Corporation
  • Takeda
  • OncoImmune/Merck (MSD)
  • Regimmune Corporation
  • Jazz Pharmaceuticals
  • Millennium Pharmaceuticals/Takeda Oncology
  • Roche-Genentech
  • Bristol-Myers Squibb
  • Xenikos
  • Synthetic Biologics
  • Equillium/Biocon
  • CTI BioPharma
  • Novartis
  • GlaxoSmithKline
  • And Many Others

 

Request for free Sample Report: https://www.delveinsight.com/sample-request/graft-versus-host-disease-gvhd-market

 

Scope of GVHD Market Report:

  • The report covers the descriptive overview of GVHD, explaining its causes, signs and symptoms, pathophysiology, and currently available therapies.
  • Comprehensive insight has been provided into the GVHD epidemiology and treatment in the 7MM.
  • Additionally, an all-inclusive account of both the current and emerging therapies for GVHD is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of GVHD market; historical and forecasted is included in the report, covering drug outreach in the 7MM.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global GVHD market.

 

 

 

Some of GVHD Therapies are:

  • Obnitix (MC0518)
  • MaaT013
  • Leukotac (Inolimomab)
  • SNDX-6532 (Axatilimab; GvHD B6352)
  • KD025 (Belumosudil)
  • Calquence (Acalabrutinib)
  • Tysabri (Natalizumab)
  • Efavaleukin Alfa (AMG 592)
  • Daurismo (Glasdegib)
  • AbGn-168H (Neihulizumab)
  • CSL 964 Alpha-1 antitrypsin (AAT)
  • Itacitinib
  • Entyvio (Vedolizumab; MLN0002)
  • MK-7110 (CD24Fc)
  • RGI-2001
  • Defitelio (Defibrotide)
  • Ninlaro (MLN 9708, MLN2238, Ixazomib)
  • Gazyva (Obinutuzumab)
  • Orencia (Abatacept)
  • T-Guard
  • SYN-004 (ribaxamase)
  • EQ001 (Itolizumab; Bmab600)
  • Pacritinib (Epjevy; ONX-0803)
  • Farydak (LBH-589, Panobinostat)
  • Benlysta (Belimumab)
  • And Many Others

 

Request for free Sample Report: https://www.delveinsight.com/sample-request/graft-versus-host-disease-gvhd-market

 

Key Questions of Graft Versus Host Disease Market are:

  • What was the GvHD Market share (%) distribution in 2018 and how it would look like in 2030?
  • What would be the GvHD total market size as well as market size by therapies across the 7MM during the study period (2018–2030)?
  • What are the key findings pertaining to the market across the 7MM and which country will have the largest GvHD market size during the study period (2018–2030)?
  • At what CAGR, the GvHD market is expected to grow in the 7MM during the study period (2018–2030)?
  • What would be the GvHD market outlook across the 7MM during the study period (2018–2030)?
  • What would be the GvHD market growth till 2030 and what will be the resultant market size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and a subsequent analysis of the associated trends?
  • GvHD patient types/pool where unmet need is more and whether emerging therapies will be able to address the residual unmet need?
  • How emerging therapies are performing on the parameters like efficacy, safety, route of administration (RoA), treatment duration and frequencies on the basis of their clinical trial results?
  • Among the emerging therapies, what are the potential therapies which are expected to disrupt the GvHD market?

 

Request for free Sample Report: https://www.delveinsight.com/sample-request/graft-versus-host-disease-gvhd-market

 

Table of Contents:

1. Key Insights

2. Executive Summary of Graft versus host disease (GVHD)

3. Competitive Intelligence Analysis for Graft versus host disease (GVHD)

4. Graft versus host disease (GVHD): Market Overview at a Glance

5. Graft versus host disease (GVHD): Disease Background and Overview

6. Patient Journey

7. Graft versus host disease (GVHD) Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Unmet Needs

10. Key Endpoints of Graft versus host disease (GVHD) Treatment

11. Marketed Products

List to be continued in report

12. Emerging Therapies

List to be continued in report

13. Graft versus host disease (GVHD): Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Graft versus host disease (GVHD)

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/graft-versus-host-disease-gvhd-market